Novo Nordisk' (NVO) Says Victoza Approved in US as Type 2 Diabetes Treatment Indicated to Reduce Risk of Three Cardiovascular Events
Tweet Send to a Friend
The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
